-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
The CRISPR-Cas9 Toolkit: Moving From Bench to Bedside
Posted: June 2017 By Cynthia L. Kryder, MS Decades of immunology research have shown that it is possible to harness the power of the immune system to fight cancer. In particular, recent discoveries regarding the regulation of T-cell responses have contributed to the development of genomically targeted agents and immune checkpoint therapies that have improved…
-
An Argument for a Large-Scale Low-Dose CT Lung Cancer Screening Trial in France
Posted: June 2017 By Bernard Milleron, MD, and Sébastien Couraud, MD, PhD Large-scale lung cancer screening trials have been successfully conducted in several countries, and formal screening recommendations have been made based on this key research. For example, the U.S. National Lung Screening Trial (NLST) demonstrated in 2011 that annual screening by low-dose computed tomography…
-
Lung Cancer Screening Is Cost Effective
Posted: June 2017 By John K. Field, PhD, FRCPath and James L. Mulshine, MD, PhD There is now robust and consistent evidence for the cost-effectiveness of lung cancer computed tomography (CT) screening as delineated in the recent analysis from ten Haaf and colleagues in PLOS Medicine.1 They have used microsimulation modeling analysis based on the…
-
Interview with Bruce Johnson, MD, 2017-2018 ASCO President
Posted: June 2017 Long-term IASLC member Bruce E. Johnson, MD, will serve as the 2017– 2018 President of the American Society of Clinical Oncology (ASCO) upon the conclusion of the 2017 ASCO Annual Meeting. Dr. Johnson describes his experience, vision, and goals for the field of thoracic oncology and oncology in general for IASLC Lung…
-
IASLC International Mentorship Program Boosts Early Careers, Fosters International Collaboration
Posted: April 2017 By Keightley Amen, BA, ELS To help ensure that high-quality thoracic oncology care is available throughout the world and well into the future, the IASLC offers an International Mentorship Program to support early-career physicians and researchers from economically developing countries. The competitive program provides each winner with a full scholarship to the…
-
NCI Formulary Holds Promise to Speed Clinical Trials
Posted: April 2017 By Erik T. MacLaren, PhD On January 11, the National Cancer Institute (NCI) launched a virtual agent formulary (NCI Formulary): a new public-private partnership designed to speed access to targeted therapies and combinations of cancer-fighting drugs by oncology researchers at the 69 NCI-Designated Cancer Centers. IASLC Lung Cancer News discussed the details…
-
Immunotherapy in Lung Cancer: How Can Nurses and Allied Health Teams Support Patient Care?
Posted: April 2017 By Anne Fraser, Oncology Nurse Practitioner Immunotherapy has changed the landscape of lung cancer treatment, offering hope to advanced lung cancer patients. Immunotherapy works by activating the patient’s immune system, helping it to better fight and destroy the cancer cells. Cancer cells evade death from T cells by expressing PD-L1 (programmed death…
-
Best of the IASLC 17th World Conference on Lung Cancer in Lima, Peru, February 2017
Posted: April 2017 By Luis E. Raez, MD The International Association for the Study of Lung Cancer (IASLC) and the Peruvian Oncology Research Group (GECO) organized and hosted the “Best of the IASLC 17th World Conference on Lung Cancer (WCLC)” in Lima, Peru, on February 9–10, 2017. The conference was very successful; almost 200 doctors…
-
Speedbumps on the Road to Robust Low-Dose Computed Tomography Lung Cancer Screening National Implementation
Posted: April 2017 By James L. Mulshine, MD, PhD and John K. Field, PhD, FRCPath Administration (VHA) clinicians reported their experience in implementing lowdose computed tomography (CT) lung cancer screening at 8 VHA hospitals.1 In this experience, 2,106 subjects were screened from July 2013 to June 30, 2015, which resulted in the diagnosis of 31…
-
Former MD Anderson President Dr. Charles A. LeMaistre Passes Away at 92
Posted: April 2017 By Waun Ki Hong, MD Charles M. LeMaistre (1924–2017) Charles A. LeMaistre, MD, past president of The University of Texas MD Anderson Cancer Center and a pioneer in cancer prevention and a strong advocate against tobacco use, passed away on January 28, 2017, in Houston at the age of 92. LeMaistre came…